The Use of a Cholinesterase Inhibitor Review Committee in Long-Term Care

Journal of the American Medical Directors Association

Volumn 8, Issue 4, 2007, Pages 243-247

  Lee, Joyce ^a,b,c   Monette, Johanne ^a,b   Sourial, Nadia ^b   Monette, Michele ^b,d   Bergman, Howard ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

Alzheimer disease; Cholinesterase inhibitors; dementia; discontinuation; long term care; review committee

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; RIVASTIGMINE;

AGED; ALZHEIMER DISEASE; ARTICLE; BEHAVIOR; CANADA; COGNITION; COHORT ANALYSIS; DAILY LIFE ACTIVITY; DEATH; DEMENTIA; DIFFUSE LEWY BODY DISEASE; DRUG USE; DRUG WITHDRAWAL; FAMILY; FEMALE; FRONTOTEMPORAL DEMENTIA; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MEDICAL RECORD REVIEW; MULTIINFARCT DEMENTIA; RETROSPECTIVE STUDY; ADVISORY COMMITTEE; DECISION MAKING; NEUROPSYCHOLOGICAL TEST; NURSING HOME; PATIENT SELECTION; PILOT STUDY;

ADVISORY COMMITTEES; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COHORT STUDIES; DECISION MAKING; DEMENTIA; FEMALE; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; NURSING HOMES; PATIENT SELECTION; PILOT PROJECTS; QUEBEC;

EID: 34248158771     PISSN: 15258610     EISSN: 15389375     Source Type: Journal    
DOI: 10.1016/j.jamda.2007.02.007     Document Type: Article

References (22)

1. Patterson C., Gauthier S., Bergman H., et al. The recognition, assessment and management of dementing disorders: Conclusions from the Canadian Consensus Conference on Dementia. Can J Neurol Sci 28 Suppl 1 (2001) S3-S16
2. Guidelines abstracted from the American Academy of Neurology's Dementia Guidelines for Early Detection, Diagnosis, and Management of Dementia. J Am Geriatr Soc 51 (2003) 869-873
3. National Institute for Health and Clinical Excellence. Donepezil, galantamine, rivastigmine (review) & memantine for the treatment of Alzheimer disease, NICE (2006). http://www.nice.org.uk/ Available at: http://www.nice.org.uk/. Accessed December 9, 2006.
4. Hebert R., Dubois M.F., Wolfson C., Chambers L., and Cohen C. Factors associated with long-term institutionalization of older people with dementia: Data from the Canadian Study of Health and Aging. J Gerontol A Biol Sci Med Sci 56 11 (2001) M693-M699
5. Tariot P.N., Cummings J.L., Katz I.R., et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. J Am Geriatr Soc 49 (2001) 1590-1599
6. Khang P., Weintraub N., and Espinoza R.T. The use, benefits, and costs of cholinesterase inhibitors for Alzheimer's dementia in long-term care: Are the data relevant and available?. J Am Med Dir Assoc 5 (2004) 249-255
7. Holroyd S. Managing dementia in long-term care settings. Clin Geriatr Med 20 (2004) 83-92
8. Mills E.J., and Chow T.W. Randomized controlled trials in long-term care residents with dementia: A systematic review. J Am Med Dir Assoc 4 (2003) 302-307
9. Winblad B., Kilander L., Eriksson S., et al. Donepezil in patients with severe Alzheimer's disease: Double-blind, parallel-group, placebo-controlled study. Lancet 367 (2006) 1057-1065
10. Vantelon C., Gilbert S., Kerneis S., Wolmark Y., Legrain S., and Kergoat M.J. [Cholinesterase inhibitor therapy in long term care settings]. Rev Med Interne 27 (2006) 588-594 French
11. Rainer M., Mucke H.A., Kruger-Rainer C., Kraxberger E., Haushofer M., and Jellinger K.A. Cognitive relapse after discontinuation of drug therapy in Alzheimer's disease: Cholinesterase inhibitors versus nootropics. J Neural Transm 108 (2001) 1327-1333
12. Singh S., and Dudley C. Discontinuation syndrome following donepezil cessation. Int J Geriatr Psychiatry 18 (2003) 282-284
13. Minett T.S., Thomas A., Wilkinson L.M., et al. What happens when donepezil is suddenly withdrawn?. An open label trial in dementia with Lewy bodies and Parkinson's disease with dementia. Int J Geriatr Psychiatry 18 (2003) 988-993
14. Regie de l'assurance maladie de Quebec. Liste des medicaments d'exception et des indications reconnues pour leur paiment. RAMQ, 2006. Available at: http://www.ramq.gouv.qc.ca/fr/professionnels/listmed/pdf/modification/an nexe_9.pdf. Accessed June 6, 2006.
15. Folstein M.F., Folstein S.E., and McHugh P.R. "Mini-mental state": A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12 (1975) 189-198
16. Bellelli G., Frisoni G.B., Bianchetti A., and Trabucchi M. The Bedford Alzheimer Nursing Severity scale for the severely demented: Validation study. Alzheimer Dis Assoc Disord 11 (1997) 71-77
17. Auer S.R., Monteiro I.M., and Reisberg B. The Empirical Behavioral Pathology in Alzheimer's Disease (E-BEHAVE-AD) Rating Scale. Int Psychogeriatr 8 (1996) 247-266
18. Ables A.Z., and Baughman III O.L. Antidepressants: Update on new agents and indications. Am Fam Physician 67 (2003) 547-554
19. Haddad P.M. Antidepressant discontinuation syndromes. Drug Saf 24 (2001) 183-197
20. Vaswani M., Linda F.K., and Ramesh S. Role of selective serotonin reuptake inhibitors in psychiatric disorders: A comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry 27 (2003) 85-102
21. O'Brien C.P. Benzodiazepine use, abuse, and dependence. J Clin Psychiatry 66 Suppl 2 (2005) 28-33
22. Chouinard G. Issues in the clinical use of benzodiazepines: Potency, withdrawal, and rebound. J Clin Psychiatry 65 Suppl 5 (2004) 7-12